1
|
Affiliation(s)
- G Cianchini
- Department of Dermatology, Cristo Re Hospital, 00167, Rome, Italy
| | - D Lazzeri
- Plastic Reconstructive and Aesthetic Surgery, Villa Salaria Clinic, 00167, Rome, Italy
| | - F Nicoli
- Plastic Reconstructive and Aesthetic Surgery, Villa Salaria Clinic, 00167, Rome, Italy.,Department of Plastic and Reconstructive Surgery, University of Rome "Tor Vergata", 00167, Rome, Italy
| | - M Pierotti
- Gubbio and Gualdo Tadino General Hospital, Gubbio, Italy
| |
Collapse
|
2
|
van Harten W, Stanta G, Bussolati G, Riegman P, Hoefler G, Becker K, Folprecht G, Truini M, Haybaeck J, Buiga R, Dono M, Bagg A, López Guerrero J, Zupo S, Lemare F, de Lorenzo F, Goedbloed N, Razavi D, Lövey J, Cadariu P, Rollandi G, Paparo F, Pierotti M, Ciuleanu T, De Paoli P, Weiner G, Saghatchian M, Lombardo C. Report from the OECI Oncology Days 2014. Ecancermedicalscience 2014; 8:496. [PMID: 25624877 PMCID: PMC4303612 DOI: 10.3332/ecancer.2014.496] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Indexed: 11/06/2022] Open
Abstract
The 2014 OECI Oncology Days was held at the 'Prof. Dr. Ion Chiricuta' Oncology Institute in Cluj, Romania, from 12 to 13 June. The focus of this year's gathering was on developments in personalised medicine and other treatment advances which have made the cost of cancer care too high for many regions throughout Europe.
Collapse
Affiliation(s)
- Wh van Harten
- The Netherlands Cancer Institute, Amsterdam,The Netherlands
| | - G Stanta
- Department of Medical Sciences, University of Trieste, Trieste, Italy
| | - G Bussolati
- Department of Medical Sciences, University of Torino, Torino, Italy
| | - P Riegman
- Erasmus Medical Centre, Rotterdam, The Netherlands
| | - G Hoefler
- Johannes Haybaeck, Institute of Pathology, Medical University of Graz, Graz, Austria
| | - Kf Becker
- Institute of Pathology, Technische Universität München, München, Germany
| | - G Folprecht
- University Cancer Centre, University Hospital Carl Gustav Carus, Dresden, Germany
| | - M Truini
- IRCCS AOU San Martino/IST National Cancer Institute of Genoa, Genoa, Italy
| | - J Haybaeck
- Johannes Haybaeck, Institute of Pathology, Medical University of Graz, Graz, Austria
| | - R Buiga
- The Oncology Institute "Prof. Dr. Ion Chircuţă", Cluj-Napoca, Romania
| | - M Dono
- IRCCS AOU San Martino/IST, National Cancer Institute of Genoa, Italy
| | - A Bagg
- Hematology, University of Pennsylvania, PA, USA
| | | | - S Zupo
- IRCCS AOU San Martino/IST, National Cancer Institute of Genoa, Italy
| | - F Lemare
- Clinical Pharmacy Department, Gustave Roussy Comprehensive Cancer Centre, Villejuif, France
| | - F de Lorenzo
- European Cancer Patient Coalition, Brussels, Belgium
| | - N Goedbloed
- The Netherlands Cancer Institute, Amsterdam,The Netherlands
| | - D Razavi
- Institut Jules Bordet et Université Libre de Bruxelles, Clinique de Psycho-Oncologie et des Soins Supportifs, Brussels, Belgium
| | - J Lövey
- National Institute of Oncology, Budapest, Hungary
| | - Pa Cadariu
- The Oncology Institute "Prof. Dr. Ion Chircuţă", Cluj-Napoca, Romania
| | - Ga Rollandi
- Department of Radiology, E.O. Ospedali Galliera, Mura della Cappuccine, Genoa, Italy
| | - F Paparo
- Department of Radiology, E.O. Ospedali Galliera, Mura della Cappuccine, Genoa, Italy
| | - M Pierotti
- IRCCS Fondazione Istituto Nazionale Tumori Milan, Milan, Italy
| | - T Ciuleanu
- The Oncology Institute "Prof. Dr. Ion Chircuţă", Cluj-Napoca, Romania
| | - P De Paoli
- Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | | | - M Saghatchian
- Medical Oncology Department, Gustave Roussy Comprehensive Cancer Centre, Villejuif, France
| | - Claudio Lombardo
- Organisation of the European Cancer Institutes, C/o SOS Europe, Genoa, Italy
| |
Collapse
|
3
|
Falvella F, Cheli S, Maggi C, Iacovelli R, Pierotti M, Gariboldi M, Martinetti A, De Braud F, Bossi I, Di Bartolomeo M, Sottotetti E, Ricchini F, Clementi E, Pietrantonio F. Prospective Observational Study for Dpyd and Ugt1A1 Deficiency-Associated Toxicity in Patients with Metastatic Colorectal Cancer (Mcrc) Receiving Triplet Chemotherapy with Capecitabine, Irinotecan and Oxaliplatin (Coi). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu333.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Mazza R, Lina M, Boffi R, Invernizzi G, De Marco C, Pierotti M. Taking care of smoker cancer patients: a review and some recommendations. Ann Oncol 2010; 21:1404-1409. [DOI: 10.1093/annonc/mdp599] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
|
5
|
Pierotti M, Pricl S, Pilotti S, Negri T, Tamborini E. 113 Molecular modelling of KIT and PDGRA mutant forms to predict sensitivity to new drugs in GISTs. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)70103-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
6
|
Boyle P, Anderson B, Andersson L, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H, Baselga J, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox B, Currow D, Dangou JM, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick J, Forstmane M, Garaci E, Gavin A, Kakizoe T, Kasler M, Keita N, Kerr D, Khayat D, Khleif S, Khuhaprema T, Knezevic T, Kubinova R, Mallath M, Martin-Moreno J, McCance D, McVie J, Merriman A, Ngoma T, Nowacki M, Orgelbrand J, Park JG, Pierotti M, Ashton L, Puska P, Escobar C, Rajan B, Rajkumar T, Ringborg U, Robertson C, Rodger A, Roovali L, Santini L, Sarhan M, Seffrin J, Semiglazov V, Shrestha B, Soo K, Stamenic V, Tamblyn C, Thomas R, Tuncer M, Tursz T, Vaitkiene R, Vallejos C, Veronesi U, Wojtyla A, Yach D, Yoo KY, Zatonski W, Zaridze D, Zeng YX, Zhao P, Zheng T. Need for global action for cancer control. Ann Oncol 2008; 19:1519-21. [DOI: 10.1093/annonc/mdn426] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, Pierotti M, Spinelli P, Radice P. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21:1698-707. [PMID: 12721244 DOI: 10.1200/jco.2003.09.118] [Citation(s) in RCA: 125] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
PURPOSE Familial adenomatous polyposis (FAP), caused by a mutation in the APC gene, is a colorectal cancer predisposition syndrome associated with several other clinical conditions. The severity of the FAP is related to the position of the inherited mutation in the APC gene. We analyzed a large series of FAP patients to identify associations among major clinical manifestations and to correlate the mutation site with specific disease manifestations. MATERIALS AND METHODS APC mutations were identified in 953 FAP patients from 187 families. We used unconditional logistic regression models and a method involving generalized estimating equations to investigate the association between genotype and phenotype. We used multiple correspondence analysis to represent the interrelationships of a multiway contingency table of the considered variables. RESULTS APC germline mutations were located between codons 156 and 2011 of the APC gene. Mutations spanning the region between codons 543 and 1309 were variable, but strongly associated with congenital hypertrophy of retinal pigment epithelium. Mutations between codons 1310 and 2011 were associated with a six-fold risk of desmoid tumors relative to the low-risk reference region (159 to 495). Mutations at codon 1309 were associated with early development of colorectal cancer. Mutations between codons 976 and 1067 were associated with a three- to four-fold increased risk of duodenal adenomas. The cumulative frequency of extracolonic manifestations was highest for mutations between codons 976 and 1067, followed by mutations between 1310 and 2011. CONCLUSION Analysis of the relation between APC mutation site and phenotype identifies subgroups of FAP patients at high risk for major extracolonic disease, which is useful for surveillance and prevention.
Collapse
Affiliation(s)
- L Bertario
- Division of Predictive and Preventive Medicine, Department of Experimental Oncology, National Cancer Institute, Via Venezian 1 20133 Milan, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Casadei S, Cortesi L, Pensotti V, Radice P, Pierotti M, Amadori D, Calistri D. Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method. Br J Cancer 2001; 85:845-9. [PMID: 11556835 PMCID: PMC2375072 DOI: 10.1054/bjoc.2001.1988] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
We describe the Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method set up for a sensitive and preliminary rapid screening of BRCA1 mutations. We analysed exons 11 and 16, which are known to cover slightly more than 70% of the whole coding region of the gene, subdivided into 4 amplicons and labelled with different fluorescent dUTPs. MD-CFLP was first utilised on a panel of 30 DNA samples in which the presence of single-base substitutions or small deletions/insertions had been previously identified by direct sequencing as gold standard, in order to define the optimal conditions in terms of PCR amplification and temperature of digestion. In a second step, we blindly analysed 21 DNA samples by MD-CFLP to verify its reliability. The sensitivity and specificity of MD-CFLP were both 100% in the first study, and 80% and 94%, respectively, in the blind sample assay. Our results demonstrate the capability of the MD-CFLP method to detect DNA sequence alterations in fragments of more than 1 kb. We conclude that CFLP is a powerful tool in mutational analysis, offering reliable results in a shorter time and at a lower cost than conventional methods, and its potential can be enhanced when internal fluorescent labelling and laser detection are used.
Collapse
Affiliation(s)
- S Casadei
- Istituto Oncologico Romagnolo, 47100 Forlì, Italy
| | | | | | | | | | | | | |
Collapse
|
9
|
Calistri D, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, Sala P, Eboli M, Andreola S, Russo A, Pierotti M, Bertario L, Ranzani GN. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Int J Cancer 2000. [PMID: 10719736 DOI: 10.1002/(sici)1097-0215(20000120)89:1<87::aid-ijc14>3.0.co;2-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited syndrome linked to DNA-mismatch-repair (MMR) gene defects, which also account for microsatellite instability (MSI) in tumour tissues. Diagnosis is based mainly on family history, according to widely accepted criteria (Amsterdam Criteria: AC). Aim of this work was to assess MSI in colorectal-cancer patients with suspected genetic predisposition, and to verify whether MSI represents a tool to manage MMR gene (hMSH2 and hMLH1) mutation analysis. We investigated 13 microsatellites (including the 5 NCI/ICG-HNPCC markers) in 45 patients with suspected hereditary predisposition (including 16 subjects from HNPCC families fulfilling the AC). We found MSI-H (high frequency of instability, i.e., in > or =30% of the markers) in 85% of the HNPCC patients and in 16% of the non-HNPCC subjects. The 5 NCI/ICG-HNPCC microsatellites proved to be the most effective in detecting MSI, being mononucleotide repeats the most unstable markers. We investigated the association between hMSH2- and hMLH1 gene mutations and MSI. Our results indicate that AC are highly predictive both of tumour instability and of MMR-gene mutations. Therefore, as the most likely mutation carriers, HNPCC subjects might be directly analyzed for gene mutations, while to test for MSI in selected non-HNPCC patients and to further investigate MMR genes in MSI-H cases, appears to be a cost-effective way to identify subjects, other than those from kindred fulfilling AC, who might benefit from genetic testing.
Collapse
Affiliation(s)
- D Calistri
- Dipartimento di Genetica e Microbiologia, University of Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Calistri D, Presciuttini S, Buonsanti G, Radice P, Gazzoli I, Pensotti V, Sala P, Eboli M, Andreola S, Russo A, Pierotti M, Bertario L, Ranzani GN. Microsatellite instability in colorectal-cancer patients with suspected genetic predisposition. Int J Cancer 2000; 89:87-91. [PMID: 10719736 DOI: 10.1002/(sici)1097-0215(20000120)89:1<87::aid-ijc14>3.0.co;2-9] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Hereditary non-polyposis colorectal cancer (HNPCC) is a dominantly inherited syndrome linked to DNA-mismatch-repair (MMR) gene defects, which also account for microsatellite instability (MSI) in tumour tissues. Diagnosis is based mainly on family history, according to widely accepted criteria (Amsterdam Criteria: AC). Aim of this work was to assess MSI in colorectal-cancer patients with suspected genetic predisposition, and to verify whether MSI represents a tool to manage MMR gene (hMSH2 and hMLH1) mutation analysis. We investigated 13 microsatellites (including the 5 NCI/ICG-HNPCC markers) in 45 patients with suspected hereditary predisposition (including 16 subjects from HNPCC families fulfilling the AC). We found MSI-H (high frequency of instability, i.e., in > or =30% of the markers) in 85% of the HNPCC patients and in 16% of the non-HNPCC subjects. The 5 NCI/ICG-HNPCC microsatellites proved to be the most effective in detecting MSI, being mononucleotide repeats the most unstable markers. We investigated the association between hMSH2- and hMLH1 gene mutations and MSI. Our results indicate that AC are highly predictive both of tumour instability and of MMR-gene mutations. Therefore, as the most likely mutation carriers, HNPCC subjects might be directly analyzed for gene mutations, while to test for MSI in selected non-HNPCC patients and to further investigate MMR genes in MSI-H cases, appears to be a cost-effective way to identify subjects, other than those from kindred fulfilling AC, who might benefit from genetic testing.
Collapse
Affiliation(s)
- D Calistri
- Dipartimento di Genetica e Microbiologia, University of Pavia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Marchetti A, Pellegrini S, Sozzi G, Bertacca G, Gaeta P, Buttitta F, Carnicelli V, Griseri P, Chella A, Angeletti CA, Pierotti M, Bevilacqua G. Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br J Cancer 1998; 78:73-8. [PMID: 9662254 PMCID: PMC2062949 DOI: 10.1038/bjc.1998.445] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Lung cancer is strictly associated with tobacco smoking. Tumours developed in non-smoking subjects account for less than 10% of all lung cancers and show peculiar histopathological features, being prevalently adenocarcinomas. A number of genetic data suggest that their biological behaviour may be different from that of lung tumours caused by smoking, however the number of cases investigated to date is too low to draw definitive conclusions. We have examined the status of p53 and K-ras genes and the presence of loss of heterozygosity (LOH) at the FHIT locus in a series of 35 lung adenocarcinomas that developed in subjects who had never smoked. Results were compared with those obtained in a series of 35 lung adenocarcinomas from heavy-smoking subjects. In the group of non-smoking subjects p53 mutations and LOH at the FHIT locus were present in seven (20%) cases, and the two alterations were constantly associated (P < 0.0001), whereas they were not related in the series of carcinomas caused by smoking. In tumours developed in heavy-smoking subjects, the frequency of LOH at the FHIT locus was significantly higher (P = 0.006) than in tumours from non-smoking subjects. The frequency of p53 mutations in adenocarcinomas caused by smoking was not different from that seen in non-smoking subjects. However, in the group of smoking subjects we observed mostly G:C --> T:A transversions, whereas frameshift mutations and G:C --> A:T transitions were more frequently found in tumours from non-smoking subjects. No point mutations of the K-ras gene at codon 12 were seen in subjects who had never smoked, whereas they were present (mostly G:C --> T:A transversions) in 34% of tumours caused by smoking (P = 0.002). Our data suggest that lung adenocarcinomas developed in subjects who had never smoked represent a distinct biological entity involving a co-alteration of the p53 gene and the FHIT locus in 20% of cases.
Collapse
Affiliation(s)
- A Marchetti
- Department of Oncology, University of Pisa, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M, Rilke F. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 1997; 151:1417-23. [PMID: 9358768 PMCID: PMC1858069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Neoplastic growth is usually dependent on blood supply, and it is commonly accepted that this is provided by the formation of new vessels. However, tumors may be able to grow without neovascularization if they find a suitable vascular bed available. We have investigated the pattern of vascularization in a series of 500 primary stage I non-small-cell lung carcinomas. Immunostaining of endothelial cells has highlighted four distinct patterns of vascularization. Three patterns (which we called basal, papillary, and diffuse) have in common the destruction of normal lung and the production of newly formed vessels and stroma. The fourth pattern, which we called alveolar or putative nonangiogenic, was observed in 16% (80/500) of the cases and is characterized by lack of parenchymal destruction and absence of both tumor associated stroma and new vessels. The only vessels present were the ones in the alveolar septa, and their presence highlighted, through the whole tumor, the lung alveoli filled up by the neoplastic cells. This observation suggests that, if an appropriate vascular bed is available, a tumor can exploit it and grows without inducing neo-angiogenesis. This could have implications for strategies aimed at inhibiting tumor growth by vascular targeting or inhibition of angiogenesis.
Collapse
Affiliation(s)
- F Pezzella
- Department of Histopathology, University College London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15:2858-65. [PMID: 9256129 DOI: 10.1200/jco.1997.15.8.2858] [Citation(s) in RCA: 199] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
PURPOSE This study investigated the frequency of the expression and prognostic significance of a panel of immunocytochemical markers in resected non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS A total of 515 cases of pathologic stage I NSCLC were analyzed. The median follow-up time of surviving patients was 102 months. The following immunocytochemical markers were tested: blood group A and precursors of blood antigens; laminin receptor; c-erbB1/epidermal growth factor receptor (EGFR) and c-erbB2/Neu; BCl2; p53; and angiogenesis. Kaplan-Meier estimates of survival and time to recurrence were calculated for clinical variables and biologic markers using the Cox model for multivariate analysis. RESULTS The pathologic tumor extension (pT) represented the most powerful prognostic factor for survival (P = .0008) and time to recurrence (P = .0007). None of the immunocytochemical markers emerged as an independent predictive factor for survival. Bcl2-positive tumors showed a better time to recurrence (P = .03), but the difference lost statistical significance in the multivariate analysis. Of interest, in the group of 137 patients classified as pT1N0, both EGFR expression and nonangiogenic type of vascular pattern were associated with a poorer survival (P = .02). However, data derived from subset analysis must be interpreted cautiously. CONCLUSION Our findings do not support a relevant prognostic role of immunocytochemical markers in NSCLC. The evidence is not sufficient to alter clinical practice or even to restrict clinical trials of adjuvant treatments to predefined biologic subsets of patients.
Collapse
Affiliation(s)
- U Pastorino
- Department of Thoracic Surgery, Royal Brompton Hospital, London, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Pierotti M. V. Cutaneous melanoma: Genetics and molecular biology. Eur J Cancer 1994. [DOI: 10.1016/0959-8049(94)90441-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Aiello A, Delia D, Borrello MG, Biassoni D, Giardini R, Fontanella E, Pezzella F, Pulford K, Pierotti M, Della Porta G. Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry 1992; 13:502-9. [PMID: 1633729 DOI: 10.1002/cyto.990130509] [Citation(s) in RCA: 59] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The bcl-2 proto-oncogene, rearranged and deregulated in B-cell lymphomas bearing the t(14;18) translocation, encodes an inner mitochondrial membrane protein that blocks apoptotic cell death. We have developed a sensitive immunofluorescence assay for the single- and multicolor flow cytometric analysis of bcl-2 protein in relation to other markers and cell cycle, based on a fixation-permeation step of cells with paraformaldehyde and Triton X100 and the use of a bcl-2 specific monoclonal antibody (MoAb). As an application of this method, we have examined the expression of bcl-2 in normal and neoplastic lymphoid cells. We have found that greater than 80% of normal T-and B-cells are bcl-2 positive; following in vitro mitogen activation, the bcl-2 reactivity decreased slightly in the former but markedly in latter cells. In both cases the bcl-2 expression was not restricted to a specific phase of the cell cycle, as evidenced by two-color analysis. On lymphoblastoid cell lines, the bcl-2 staining intensity was variable and not necessarily correlated to molecular rearrangements of the bcl-2 gene. Among fresh B-cell non-Hodgkin's lymphomas (B-NHL), most sporadic Burkitt's cases were bcl-2 negative. Of four centroblastic-centrocytic cases with rearrangements of the bcl-2 gene, only two presented elevated amounts of bcl-2 protein, indicating that the levels of bcl-2 are not diagnostic of the translocation.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- A Aiello
- Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Sozzi G, Bertoglio MG, Borrello MG, Gianì S, Pilotti S, Pierotti M, Della Porta G. Chromosomal abnormalities in a primary small cell lung cancer. Cancer Genet Cytogenet 1987; 27:45-50. [PMID: 3034398 DOI: 10.1016/0165-4608(87)90259-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
A cytogenetic analysis of a fresh primary tumor specimen of small cell lung cancer showed a del(3)(p14p23) in the majority of metaphases. Additional clonal changes were found in the karyotype. No abnormalities for Ha-ras, Ki-ras, N-ras, myb, or myc were detected by Southern blot analysis of the tumor DNA.
Collapse
|
17
|
Parmiani G, Sensi ML, Carbone G, Colombo M, Pierotti M, Ballinari D, Hilgers J, Hilkens J. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice. Int J Cancer 1982; 29:323-32. [PMID: 7068280 DOI: 10.1002/ijc.2910290316] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
To test whether alloimmunization with H-2 or/and non-H-2 different normal tissues may increase the immunity to syngeneic tumors, groups of BALB/c (H-2d) mice were immunized with a series of allogeneic lymphoid cells and then challenged i.p. with syngeneic lymphoma cells. The outgrowth of otherwise lethal doses of the Moloney virus-induced lymphoma YC8 and of its clones was inhibited in BALB/c mice immune to DBA/2 (H-2d), C3Hf (H-2k), C3H.SW (H-2b), C3H.OH (H-2o2) and to B10 background tissues but not in mice immunized to A/He, BALB.K (H-2k) or BALB.B (H-2b) normal tissues. Anti-YC8 effect was also induced by immunizing BALB/c recipients with a pool of five different allogeneic cell lines which included C3Hf, C57BL/6J (H-2b), N:NIH (H-2q), B10.M (H-2f), and DBA/2 lymphoid cells. No growth inhibition of other BALB/c lymphomas induced by Moloney virus (LSTRA), X-rays (RL male I) or urethane (UR-1) was evident in alloimmune mice. In vivo transfer of growth inhibition of YC8 was obtained with BALB/c anti-B10.D2 peritoneal exudate cells in a Winn assay. The ability of these alloimmune lymphoid cells to delay significantly the survival time of BALB/c mice injected with the mixture of immune cell and YC8 cells was abrogated by anti-Thy 1.2 plus C' treatment. In addition, nu/nu BALB/c mice were unable to develop resistance to YC8 outgrowth after alloimmunization. The results of this study show that: (1) syngeneic growth of a lymphoma can be prevented by alloimmunization with normal cells; (2) this cross-reaction involved non-H-2 antigens; (3) the phenomenon appeared to be mediated by T cells.
Collapse
|
18
|
Tress E, Pierotti M, DeLeo AB, O'Donnell PV, Fleissner E. Endogenous murine leukemia virus-encoded proteins in radiation leukemias of BALB/c mice. Virology 1982; 117:207-18. [PMID: 6278737 DOI: 10.1016/0042-6822(82)90520-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
19
|
Pierotti M, DeLeo AB, Pinter A, O'Donnell PV, Hämmerling U, Fleissner E. The GIX antigen of murine leukemia virus: an analysis with monoclonal antibodies. Virology 1981; 112:450-60. [PMID: 6167060 DOI: 10.1016/0042-6822(81)90292-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
20
|
Pierotti M. Cyclic AMP, Cell Growth, and the Immune Response. Tumori 1975. [DOI: 10.1177/030089167506100516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
21
|
Pierotti M, Ménard S. Changes of Antigenicity and Growth Rate of Murine Sarcomas Induced by a Chemical Carcinogen. Tumori 1974; 60:33-44. [PMID: 4841997 DOI: 10.1177/030089167406000104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The relation with latent period (LP) of the antigenicity (AG) and growth rate (GR) of 7,12-dimethylbenz (a) anthracene-induced sarcomas have been studied in 3 experimental situations. In the first experiment, 36 primary BALB/c sarcomas showed a decrease of AG and an increase of GR when LP increased from 10 to 26 weeks. The tumors which appeared after a short latency grew slower and were more antigenic than tumors with longer latency. In the second experiment, one antigenic C3Hf fibrosarcoma was transplanted serially in immunodepressed and normal mice and tested for AG and GR at the 1st, 3rd, 6th, 8th and 10th transplant. The same relationship between AG and GR was observed in the two lines as AG decreased while GR increased during serial transplantations. In the third experiment, two monoclonal tumors isolated from the C3Hf fibrosarcoma of the previous experiment were tested at different transplant. A decline of antigenic strengh and an increase of GR during serial transplantation was observed in both tumors. The change of AG and GR observed in these experiments cannot be explained only by immunological surveillance, and nor by a clonal selection of high GR cells preexisting in the primary tumor. It seems rather that during proliferation the malignant cells gradually lose growth control leading to an increase of GR and, at the same time, to a diminution of AG.
Collapse
|
22
|
|
23
|
Menard S, Pierotti M, Cornalba G. Antigeni individuali e antigeni comuni in sarcomi indotti da 7,12-dimetilbenzantracene nel topo. Tumori 1972. [DOI: 10.1177/030089167205800464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- S. Menard
- (Divisione di Oncologia Sperimentale A dell'Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano)
| | - M. Pierotti
- (Divisione di Oncologia Sperimentale A dell'Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano)
| | - G. Cornalba
- (Divisione di Oncologia Sperimentale A dell'Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano)
| |
Collapse
|
24
|
Pierotti M. Chemical mutagenesis in mammals and man. Tumori 1971. [DOI: 10.1177/030089167105700609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
25
|
Broccoli F, Pierotti M. [Vascularization of the adrenals in Gallus gallus]. Boll Soc Ital Biol Sper 1970; 46:392-4. [PMID: 5533917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
26
|
Coppini L, Broccoli F, Ghibellini MD, Pierotti M. [Data on the topography of the small intestine in humans]. Boll Soc Ital Biol Sper 1970; 46:253-7. [PMID: 5457922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|